HK1207008A1 - Use of thymosin alpha for treatment of purulent rhinosinusitis - Google Patents

Use of thymosin alpha for treatment of purulent rhinosinusitis

Info

Publication number
HK1207008A1
HK1207008A1 HK15107821.3A HK15107821A HK1207008A1 HK 1207008 A1 HK1207008 A1 HK 1207008A1 HK 15107821 A HK15107821 A HK 15107821A HK 1207008 A1 HK1207008 A1 HK 1207008A1
Authority
HK
Hong Kong
Prior art keywords
treatment
thymosin alpha
purulent rhinosinusitis
rhinosinusitis
purulent
Prior art date
Application number
HK15107821.3A
Other languages
English (en)
Chinese (zh)
Inventor
Hemmo A Drexhage
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of HK1207008A1 publication Critical patent/HK1207008A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK15107821.3A 2012-03-08 2015-08-13 Use of thymosin alpha for treatment of purulent rhinosinusitis HK1207008A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261608427P 2012-03-08 2012-03-08
PCT/US2013/029929 WO2013134666A1 (en) 2012-03-08 2013-03-08 Use of thymosin alpha for treatment of purulent rhinosinusitis

Publications (1)

Publication Number Publication Date
HK1207008A1 true HK1207008A1 (en) 2016-01-22

Family

ID=49117390

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107821.3A HK1207008A1 (en) 2012-03-08 2015-08-13 Use of thymosin alpha for treatment of purulent rhinosinusitis

Country Status (8)

Country Link
US (1) US20150031617A1 (xx)
EP (1) EP2838551A4 (xx)
JP (1) JP2015510887A (xx)
KR (1) KR20150035495A (xx)
CN (1) CN104507491A (xx)
CA (1) CA2866159A1 (xx)
HK (1) HK1207008A1 (xx)
WO (1) WO2013134666A1 (xx)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
AU2003223601A1 (en) * 2002-04-12 2003-10-27 King's College London ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN Beta 4
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
CN1777438A (zh) * 2003-04-23 2006-05-24 希克龙制药公司 用α胸腺肽治疗或预防呼吸病毒的感染
CA2588685A1 (en) * 2004-12-06 2006-06-15 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as cancer vaccine adjuvants
CN101204578A (zh) * 2006-12-20 2008-06-25 干春玉 一种具有调节免疫、抗组织损伤及再生修复作用的胸腺素复合制剂
CN101244262B (zh) * 2007-02-14 2011-12-28 成都地奥九泓制药厂 一种治疗细菌性感染的药物联合药剂

Also Published As

Publication number Publication date
EP2838551A1 (en) 2015-02-25
WO2013134666A1 (en) 2013-09-12
CN104507491A (zh) 2015-04-08
US20150031617A1 (en) 2015-01-29
JP2015510887A (ja) 2015-04-13
EP2838551A4 (en) 2016-02-24
KR20150035495A (ko) 2015-04-06
CA2866159A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
HRP20171474T1 (hr) Triazolopirazini kao inhibitori brd4 za uporabu u liječenju raka
HRP20180939T1 (hr) Kombinirana terapija za liječenje multiple skleroze
HK1258394A1 (zh) 治療劑傳遞
EP2670434A4 (en) TREATMENT OF TAUOPATHIA
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
GB2511470B (en) Treatment of fungal infections using alternative oxidase inhibitors
HK1246694A1 (zh) α胸腺肽用於膿毒症治療的用途
SI2812013T1 (sl) Formulacija za zdravljenje SRČ-ja
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
LT2872176T (lt) Karboranilporfirinai, skirti naudoti vėžio gydymui
ZA201308025B (en) The use of secnidazole in treating dental infections
HK1207008A1 (en) Use of thymosin alpha for treatment of purulent rhinosinusitis
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui
EP2908871A4 (en) ABSTRACT PROCESSING TECHNIQUES
GB201208770D0 (en) Compounds for use in the treatment of adenovirus infections
GB201221118D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment